Philip Fallon

Dr Philip Fallon is a medicinal chemist with 20 years’ industrial experience of small-molecule drug discovery research. Prior to his ten years’ at Domainex, Philip held research positions at BioFocus, Medivir, and Aventis and Rhone-Poulenc CropScience.

Philip has worked successfully in all stages of drug discovery, from early hit identification through to lead optimisation. He is a named inventor on several patents, has presented research at international conferences and was part of the project team which invented MIV-711, a Cathepsin K inhibitor, currently in Ph II clinical trials for osteoarthritis. During his career, Philip has gained experience in several therapeutic areas (oncology, anti-coagulants, liver disease) and target classes (proteases, protein-protein interactions including RAS, neuropilin and lysine methyltransferases).

Philip graduated from the University of Cambridge and obtained his PhD from Nottingham University working under the supervision of with Dr Mark Mascal.